PharmaPoint: Global Asthma Drug Market Growth, Demand to 2023

1
PharmaPoint Asthma - Global Drug Market Forecast
and Market Analysis to 2023 www.bigmarketresea
rch.com
2
Report Description
Big Market Research added a new research report
"PharmaPoint Asthma - Global Drug Forecast and
Market Analysis to 2023". Asthma accounts for
approximately 250,000 deaths around the world
annually, deaths that otherwise could be easily
prevented through appropriate treatment The
asthma market saw very slow growth over the past
decade, as it has become saturated with
relatively efficacious standard therapies, such
as short-acting beta-agonists (SABAs), inhaled
corticosteroids (ICSs), inhaled corticosteroids
and long-acting beta-agonists (ICS/LABAs), and
leukotriene modifiers, and has also been facing
increasing generic competition. However, the
launch of seven novel targeted biologic agents
and once-daily ICS and ICS/LABA therapies
delivered by the next-generation inhalers will
strongly drive the market growth over the next 10
years. The biologic agents will not only reshape
the market growth, but will also mark the
beginning of a new era of a personalized approach
to asthma treatment. To request more
information Visit _at_ http//www.bigmarketresearch.
com/pharmapoint-asthma-global-drug-forecast-and-an
alysis-to-2023-market
3
Report Description

• Key Questions Answered
• Asthma symptoms can be controlled in the majority
  of patients using the current standard therapies.
  Nevertheless, in around 5-10 of people with
  asthma, the disease remains symptomatic and
  inadequately controlled. Therefore, there are
  considerably high unmet needs within the
  indication. What are the main unmet needs in this
  market.Will the drugs under development fulfil
  the unmet needs of the asthma market?
• The current late-stage asthma pipeline is
  dominated by biologics that target various
  inflammatory pathways in specific patient
  subpopulations. Will the late-stage drugs make a
  significant impact on the asthma market.What
  strategies are drug developers undertaking to
  penetrate this difficult but potentially very
  lucrative market?
• Feel free to get enquire about report _at_
• http//www.bigmarketresearch.com/report-enquiry/19
  1286

4
Report Description

• Key Findings
• The main driver of the enormous expansion of the
  asthma market will be the uptake of novel
  targeted biologic agents and once-daily ICS and
  ICS/LABA therapies in the next-generation
  inhalers.
• The major global barrier for the asthma market
  will be the generic erosion of the leading brands
  for asthma treatment, such as Advair (fluticasone
  propionate/salmeterol)and Symbicort
  (budesonide/formoterol fumarate).

5
Report Description

• Companies are trying to penetrate or dominate the
  asthma market using two main approaches
• 1) developing drugs with different delivery
  devices to capitalize on long-established
  off-patent therapies
• 2) introducing biologics, in particular,
  interleukin inhibitors, to treat severe
  uncontrolled asthma.
• The largest unmet needs mainly reflect the high
  level of heterogeneity of the disease, the lack
  of patient compliance with the standard
  therapies, and the high cost of medications for
  asthma treatment. In addition, there is a lack of
  diagnostic tools to provide a reliable diagnosis
  of asthma in young children.

6
Table of Contents
1 Table of Contents 1.1 List of Tables 1.2 List
of Figures 2 Introduction 2.1 Catalyst 2.2
Related Reports 2.3 Upcoming Related Reports 3
Disease Overview 3.1 Etiology and
Pathophysiology 3.1.1 Etiology 3.1.2
Pathophysiology 3.1.3 Prognosis 3.1.4 Quality
of Life 3.2 Symptoms
7
Table of Contents
4 Epidemiology 4.1 Disease Background 4.2 Risk
Factors and Comorbidities 4.2.1 A family history
of asthma is a strong predictor for asthma in
children and adults 4.2.2 Puberty alters the
risk for asthma in boys and girls 4.2.3 Maternal
smoking during pregnancy greatly increases the
risk of childhood asthma 4.2.4 Allergens are
well-known asthma triggers 4.2.5 Common
workplace exposures account for up to 11 of
asthma cases in adults 4.2.6 Urban living
conditions, not race, increase the risk of asthma
by almost 50 4.2.7 Obesity almost triples the
risk of developing asthma 4.2.8 Asthmatics are
90 more likely to develop GERD 4.2.9 85 of
asthmatics have allergic rhinitis 4.2.10 Panic
disorders are common in asthmatics and severely
impact disease control 4.2.11 39 of asthmatics
are likely to develop depression
8
Table of Contents
4.3 Global Trends 4.3.1 US 4.3.2 France 4.3.3
Germany 4.3.4 Italy 4.3.5 Spain 4.3.6 UK 4.3.7
Japan 4.3.8 Australia 4.3.9 China 4.3.10
India 4.4 Forecast Methodology 4.4.1 Sources
Used 4.4.2 Forecast Assumptions and Methods 4.4.3
Sources Not Used 4.5 Epidemiology Forecast for
Asthma (2013-2023) 4.5.1 Lifetime Prevalent Cases
of Asthma
9
Report Description

• Scope
• Overview of asthma, including epidemiology,
  etiology, pathophysiology, symptoms, diagnosis,
  and treatment guidelines.
• Annualized asthma therapeutics market revenue,
  annual cost of therapy and treatment usage
  pattern data from 2013 and forecast for ten years
  to 2023.
• Key topics covered include strategic competitor
  assessment, market characterization, unmet needs,
  clinical trial mapping and implications for the
  asthma therapeutics market.

10
Report Description

• Pipeline analysis comprehensive data split
  across different phases, emerging novel trends
  under development, and detailed analysis of
  late-stage pipeline drugs.
• Analysis of the current and future market
  competition in the global asthma therapeutics
  market. Insightful review of the key industry
  drivers, restraints and challenges. Each trend is
  independently researched to provide qualitative
  analysis of its implications.
• Request for discount _at_ http//www.bigmarketresear
  ch.com/purchase-enquiry/191286

11
Report Description

• Reasons to buy
• Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies, and by
  identifying the companies with the most robust
  pipeline. Additionally a list of acquisition
  targets included in the pipeline product company
  list.
• Develop business strategies by understanding the
  trends shaping and driving the global asthma
  therapeutics market.
• Drive revenues by understanding the key trends,
  innovative products and technologies, market
  segments, and companies likely to impact the
  global asthma therapeutics market in future.

12
Report Description

• Formulate effective sales and marketing
  strategies by understanding the competitive
  landscape and by analysing the performance of
  various competitors.
• Identify emerging players with potentially strong
  product portfolios and create effective
  counter-strategies to gain a competitive
  advantage.
• Track drug sales in the global asthma
  therapeutics market from 2013-2023.
• Organize your sales and marketing efforts by
  identifying the market categories and segments
  that present maximum opportunities for
  consolidations, investments and strategic
  partnerships.

13
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/pharmapoint-asthm
a-global-drug-forecast-and-analysis-to-2023-market

Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone]E-MAIL
help_at_bigmarketresearch.com